Webinar Archives
- Recent
- Maestro
- Life Science
- 20th Schrödinger European User Group Meeting
- What's New
- AI in Life Sciences Series
- Drug Discovery User Group Meeting 2020
- Summer of Science Series
- Chinese Webinar Series 2020
- Multiscale Modeling for Biotherapeutics Symposium
- Biologics
- FEP
- Force Field
- Formulations
- Informatics
- Lead Optimization
- Machine Learning
- MD
- Pharmacophores
- QM
- Target Refinement
- Virtual Screening
- Materials
- 20th Schrödinger European User Group Meeting
- What's New
- Digital Transformation for Chemistry & Materials Innovation
- Summer of Science Series
- Materials Science User Group Meeting 2020
- Chinese Webinar Series 2020
- Multiscale Modeling for Biotherapeutics Symposium
- ALD
- Catalysis and Reactivity
- Formulations
- Informatics
- MD
- Machine Learning
- OLED
- Polymer
- QM
- Informatics
- Bootcamps
- India Life Sciences Seminar Series
- Global Materials Science Seminar Series 2019
- 2nd Life Science Bootcamp
- 4th Life Science Bootcamp
- 5th Life Science Bootcamp
- 6th Life Science Bootcamp
- 7th Life Science Bootcamp
- 8th Life Science Bootcamp
- 9th Life Science Bootcamp
- 1st Materials Bootcamp
- 2nd Materials Bootcamp
- Release
- Lunch and Learns
SARS-CoV-2 Main Protease Inhibitors: Physics-based Approaches to the Discovery of COVID-19 Antivirals
Drs. Abba Leffler and Leah Frye, Schrödinger and Dr. Daniel Carney, Takeda Pharmaceuticals
COVID-19 is an infectious disease caused by the SARS-CoV-2 virus. Worldwide, there have been over 240 million cases reported and close to 5 million deaths. Even though there are now several vaccines available for the disease, there is a clear need for the development of small molecule antivirals. One approach to the rapid discovery of such therapeutics is to apply physics-based methods to structures of the SARS-CoV-2 main protease, a key enzyme in the viral replication process. This talk will focus on the medicinal and computational chemistry driven discovery of main protease inhibitors. The challenges of coordinating this multi-company effort, the use of WaterMap to guide the design of inhibitors, and the use of Free-Energy Perturbation (FEP+) to predict the potencies of compounds to prioritize them for synthesis will be discussed. Biological results for key compounds will be presented.
Funding for this work is provided by Takeda, Schrödinger, Gilead, WuXi, and Google.